The trajectory of companies tied to Viagra's past presents a intricate investment picture . While the initial success generated substantial gains, generic alternatives have significantly impacted revenue. Investing in associated pharmaceutical businesses now requires a careful assessment of patent protection , evolving patient trends , and the pote